The SkinBioTherapeutics platform applies research discoveries made on the activities of lysates derived from probiotic bacteria.
SkinBioTherapeutics has raised $2.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in August 2024.
SkinBioTherapeutics's investors include Seneca Partners, Premier Miton Investors, Cynosure Capital.
SkinBioTherapeutics is headquartered in Macclesfield, United Kingdom.
The SkinBioTherapeutics platform applies research discoveries made on the activities of lysates derived from probiotic bacteria.
SkinBioTherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SkinBioTherapeutics — Funding & Investors." VCBacked, August 2, 2024, https://www.vcbacked.co/company/skinbiotherapeutics. Accessed August 18, 2026.
VCBacked. (2024). SkinBioTherapeutics — Funding & Investors. Retrieved August 18, 2026, from https://www.vcbacked.co/company/skinbiotherapeutics
{{cite web |title=SkinBioTherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/skinbiotherapeutics |website=VCBacked |access-date=August 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated